Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Bell, R.L.; Harris, R.R.
    The enzymology and pharmacology of 5-lipoxygenase and 5-lipoxygenase activating protein (1999), Clin. Rev. Allergy Immunol., 17, 91-109.
    View publication on PubMed

Inhibitors

EC Number Inhibitors Comment Organism Structure
1.13.11.34 4,4'-(2,3-dimethyl)-1,4-butanediylbis-1,2-benzenediol
-
 Rattus norvegicus
1.13.11.34 A-53162
-
 Rattus norvegicus
1.13.11.34 ABT 761 CAS: 154355-76-7 Rattus norvegicus
1.13.11.34 additional information classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198 Cavia porcellus
1.13.11.34 additional information classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198 Homo sapiens
1.13.11.34 additional information classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198 Oryctolagus cuniculus
1.13.11.34 additional information
-
 Rattus norvegicus
1.13.11.34 additional information classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198 Sus scrofa
1.13.11.34 ZD 2138
-
 Homo sapiens
1.13.11.34 ZD 2138
-
 Rattus norvegicus
1.13.11.34 zileuton
-
 Homo sapiens
1.13.11.34 zileuton
-
 Rattus norvegicus

Organism

EC Number Organism UniProt Comment Textmining
1.13.11.34 Cavia porcellus
-
-
-
1.13.11.34 Homo sapiens
-
-
-
1.13.11.34 Oryctolagus cuniculus
-
-
-
1.13.11.34 Rattus norvegicus
-
-
-
1.13.11.34 Sus scrofa
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
1.13.11.34 leukemia cell
-
 Rattus norvegicus
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
1.13.11.34 arachidonate + O2 i.e. 5,8,11,14-eicosatetraenoic acid Cavia porcellus (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
 ?
1.13.11.34 arachidonate + O2 i.e. 5,8,11,14-eicosatetraenoic acid Homo sapiens (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
 ?
1.13.11.34 arachidonate + O2 i.e. 5,8,11,14-eicosatetraenoic acid Rattus norvegicus (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
 ?
1.13.11.34 arachidonate + O2 i.e. 5,8,11,14-eicosatetraenoic acid Sus scrofa (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
 ?
1.13.11.34 arachidonate + O2 i.e. 5,8,11,14-eicosatetraenoic acid Oryctolagus cuniculus (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
 ?